Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study

被引：0
|
作者：
Maher, Keri Renee
Schafer, Danielle
Schaar, Dale
Sabo, Roy
Bandyopadhyay, Dipankar
Grant, Steven
机构：
[1] VCU Massey Canc Ctr, Richmond, VA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Virginia Commonwealth Univ, Richmond, VA USA
[4] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19015
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
    Oka, Satoko
    Ono, Kazuo
    CLINICAL CASE REPORTS, 2021, 9 (06):
  • [22] Phase I study of liposomal daunorubicin (daunoxome) in relapsed and refractory acute myeloid leukemia.
    Lerchenmüller, C
    Büchner, T
    Berdel, WE
    BLOOD, 1999, 94 (10) : 233B - 233B
  • [23] The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
    Snow, Anson
    Zeidner, Joshua F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [24] Phase I study of temozolomide in relapsed/refractory acute leukemia
    Seiter, K
    Liu, D
    Loughran, T
    Siddiqui, A
    Baskind, P
    Ahmed, T
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3249 - 3253
  • [25] Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
    Danielle Shafer
    Amanda B. Kagan
    Michelle A. Rudek
    Maciej Kmieciak
    Mary Beth Tombes
    Ellen Shrader
    Dipankar Bandyopadhyay
    Daniel Hudson
    Heidi Sankala
    Caryn Weir
    Jeffrey E. Lancet
    Steven Grant
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 281 - 290
  • [26] Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
    Shafer, Danielle
    Kagan, Amanda B.
    Rudek, Michelle A.
    Kmieciak, Maciej
    Tombes, Mary Beth
    Shrader, Ellen
    Bandyopadhyay, Dipankar
    Hudson, Daniel
    Sankala, Heidi
    Weir, Caryn
    Lancet, Jeffrey E.
    Grant, Steven
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) : 281 - 290
  • [27] Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome
    Benajiba, Lina
    Carraway, Hetty E.
    Hamad, Nada
    Stein, Eytan M.
    Yannakou, Costas K.
    Burroughs, Amy
    Harris, Scott
    Lane, Hayley
    Nguyen, Dorothy D.
    Stuart, Monic
    Vargas, Jesse
    Puissant, Alexandre
    Stegmaier, Kimberly
    DiNardo, Courtney D.
    BLOOD, 2020, 136
  • [28] Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
    Geramita, Emily
    Wang, Hong
    Bastacky, Melissa
    Cohen, Jessica
    Shallis, Rory Michael
    Badar, Talha
    Litzow, Mark R.
    Im, Annie
    BLOOD, 2022, 140 : 6187 - 6188
  • [29] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [30] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Sekiguchi, Naohiro
    Kasahara, Senji
    Miyamoto, Toshihiro
    Kiguchi, Toru
    Ohno, Hitoshi
    Takagi, Taiga
    Tachibana, Masaya
    Sumi, Hiroyuki
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Usuki, Kensuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 68 - 77
12345